Orphan Synergy Europe - Pharma Aktie
7,42EUR | -0,06EUR | -0,80% |
WKN DE: A14QXP / ISIN: FR0012127173
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 75,15 |
Emile Loria | 12,14 |
Dominique Constantini | 9,20 |
Alexis Peyroles | 4,26 |
Maryvonne Hiance | 1,94 |
Nicolas Poirier, PhD | 1,57 |
Mandarine Funds - Europe Micro Cap | 1,05 |
BSO Bio Santé | 0,55 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 42 | 51 | 61 | 67 | 55 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,62 | 0,20 | 0,43 | 0,27 | 0,04 |
Bilanz (in Mio. EUR) - Aktiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 33 | 40 | 44 | 37 | 30 |
Summe Anlagevermögen | 56 | 57 | 57 | 54 | 51 |
Summe Aktiva | 89 | 97 | 102 | 92 | 82 |
Bilanz (in Mio. EUR) - Passiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Gesamtverschuldung/ -verbindlichkeiten | 11 | 20 | 37 | 45 | 46 |
Summe Fremdkapital | 30 | 36 | 54 | 59 | 59 |
Summe Eigenkapital | 58 | 61 | 48 | 33 | 23 |
Summe Passiva | 89 | 97 | 102 | 92 | 82 |
Adresse
22, Boulevard Benoni Goullin, 44000 Nantes | |
Telefon | +33 (2) 28-29-10-10 |
Internet | http://www.ose-immuno.com |
Management
Anne-Laure Autret-Cornet
Director, Chief Financial & Administrative Officer |
Brigitte Dreno
Independent Director |
Cécile Nguyen-Cluzel
Independent Director |
Didier Hoch
Chairman |
Dominique Costantini
Chief Development & Strategy |
Eric Jean Marie Leire
Independent Director |
Jean Jacques Mention
Chief Business Officer |
Jean-Pascal Conduzorgues
Chief Manufacturing Officer |
Laurence de Schoulepnikoff
Chief Operating & Business Officer |
Linda Lebon
Chief Regulatory Officer |
Marc Dechamps
Independent Director |
Markus Goebel
Independent Director |
Martine Ortin George
Independent Director |
Maryvonne Hiance
Vice Chairman & Public Affairs Director |
Nicolas Poirier
Chief Executive Officer & Director |
Silvia Comis
Head-Clinical Development |
Thomas Guillot
Investor Relations Contact |